GeneDx Holdings (WGS) Net Margin (2020 - 2026)

GeneDx Holdings (WGS) has reported Net Margin for 7 consecutive years, with 15.5% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin fell 2603.0% year-over-year to 15.5% in Q2 2026; TTM through Jun 2026 was 23.41%, a 2379.0% decrease from a year earlier, with the FY2025 full-year figure at 4.92%, up 1220.0% from the prior year.
• Net Margin was 15.5% for Q2 2026 at GeneDx Holdings, up from 61.92% in the prior quarter.
• Over five years, Net Margin peaked at 10.53% in Q2 2025 and troughed at 503.2% in Q4 2022.
• A 5-year average of 84.0% and a median of 43.12% in 2024 frame the typical range for Net Margin.
• Across the five-year window, Net Margin slumped 43368 bps in 2022 and surged 45831 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 503.2% in 2022, then surged by 91 bps to 44.89% in 2023, then soared by 113 bps to 5.69% in 2024, then sank by 357 bps to 14.6% in 2025, then decreased by 6 bps to 15.5% in 2026.
• The last three Net Margin figures came in at 15.5% (Q2 2026), 61.92% (Q1 2026), and 14.6% (Q4 2025), per Business Quant data.